On July 16, SELLAS Life Sciences fell 8.6% in regular trading, trading at $11.73 USD/share, with Turnover of $36.72 million.
Within the Biotechnology sector where SELLAS Life Sciences belongs, among individual stocks, AbbVie up 2.75%, Amgen up 2.06%, Gilead Sciences up 1.18%, Vertex Pharmaceuticals up 0.83%, Moderna down 4.29%.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidate is Galinpepimut-S (GPS), currently in a pivotal Phase 3 REGAL trial for acute myeloid leukemia, and SLS009, a highly selective CDK9 inhibitor in Phase 2 trials for first-line AML treatment.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments